Meeting
2012 ASCO Annual Meeting
Pathologic complete response rates observed in women with locally advanced and inflammatory breast cancer receiving neoadjuvant carboplatin and paclitaxel.
Authors
Arvind Manohar Shinde
City of Hope, Duarte, CA
Arvind Manohar Shinde , John H Yim , Laura Kruper , Courtney Vito , Steven L. Chen , Isaac Benjamin Paz , Thehang H. Luu , Tomoko Tagawa , Kim Wai Yu , Sharon Wilczynski , Sally Shaw , Lalit Vora , Jinha Mark Park , George Somlo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 1035)
DOI
10.1200/jco.2012.30.15_suppl.1035
Abstract #
1035
Poster Bd #
19B
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A pilot study of dose-dense (biweekly) carboplatin plus paclitaxel with or without trastuzumab as neoadjuvant treatment for breast cancer.
First Author: Teng Zhu
Poster
2011 ASCO Annual Meeting
Correlation between miRNA and gene expression profiles and response to neoadjuvant chemotherapy in patients with locally advanced and inflammatory breast cancer.
First Author: G. Somlo
Poster
2014 ASCO Annual Meeting
Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer.
First Author: Joseph B. Babigumira
Poster
2012 ASCO Annual Meeting
Correlation between miRNA (miR) and gene expression profiles (GEP) and response to neoadjuvant chemotherapy (NT) in patients with locally advanced and inflammatory breast cancer (BC).
First Author: Sierra Mi Li